Omeprazol Apofri (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Apofri, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and Zollinger‑Ellison syndrome in adults and children. GNH USA supplies Omeprazol Apofri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Apofri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours. - Erosive esophagitis: aids in mucosal healing and symptom control. - Helicobacter pylori eradication regimens: used as adjunct therapy to improve eradication rates when combined with antibiotics.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild, transient headache reported by some patients. - Diarrhoea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Hypomagnesemia: low serum magnesium levels causing muscle cramps or cardiac arrhythmia. - Vitamin B12 deficiency: reduced absorption leading to anemia. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output. - Stevens‑Johnson syndrome: rare severe skin reaction with blistering. - Hepatotoxicity: elevated liver enzymes indicating liver stress.

When prescribing Omeprazole, clinicians should consider several safety aspects.

- Assess renal function: adjust use in patients with severe renal impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term use: evaluate need for continued therapy after 8‑12 weeks. - Pregnancy and lactation: weigh benefits against potential risks. - Elderly patients: start with the lowest effective dose and monitor closely. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, leading to loss of antiviral efficacy. - Methotrexate (high dose): increased serum levels, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring more frequent monitoring. - Digoxin: possible increase in serum concentration. - Diazepam: may increase sedative effects. - Ketoconazole: reduced absorption, diminishing antifungal activity.